These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37880168)

  • 1. Anti-factor Xa level monitoring of low-molecular-weight heparin for prevention of venous thromboembolism in critically ill patients (AXaLPE): protocol of a randomised, open-label controlled clinical trial.
    Wang C; Ning YC; Song LP; Li PJ; Wang FH; Ding MX; Jiang L; Wang M; Pei QQ; Hu SM; Wang H
    BMJ Open; 2023 Oct; 13(10):e069742. PubMed ID: 37880168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Anti-Factor Xa Levels of Patients Undergoing Colorectal Surgery Given Once-Daily Enoxaparin Prophylaxis: A Clinical Study Examining Enoxaparin Pharmacokinetics.
    Pannucci CJ; Fleming KI; Bertolaccini CB; Prazak AM; Huang LC; Pickron TB
    JAMA Surg; 2019 Aug; 154(8):697-704. PubMed ID: 31116389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Factor Xa Monitoring of Enoxaparin Thromboembolism Prophylaxis in Emergency General Surgery Patients.
    Pokrzywa CJ; Biesboer EA; Figueroa J; Al Tannir AH; de Moya M; Morris RS; Murphy PB
    J Am Coll Surg; 2023 Aug; 237(2):195-203. PubMed ID: 37039364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous thromboembolism in burns patients: Are we underestimating the risk and underdosing our prophylaxis?
    Lu P; Harms KA; Paul E; Bortz H; Lo C; Cleland H
    J Plast Reconstr Aesthet Surg; 2021 Aug; 74(8):1814-1823. PubMed ID: 33414092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard Fixed Enoxaparin Dosing for Venous Thromboembolism Prophylaxis Leads to Low Peak Anti-Factor Xa Levels in Both Head and Neck and Breast Free Flap Patients.
    Ambani SW; Bengur FB; Varelas LJ; Nguyen VT; Cruz C; Acarturk TO; Manders EK; Kubik MW; Sridharan S; Gimbel ML; Solari MG
    J Reconstr Microsurg; 2022 Nov; 38(9):749-756. PubMed ID: 35714620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients.
    Yam L; Bahjri K; Geslani V; Cotton A; Hong L
    Pharmacotherapy; 2019 Jul; 39(7):749-755. PubMed ID: 31112313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study.
    Hakeam HA; Al Duhailib Z; Alsemari M; Alwaibah RM; Al Shannan MF; Shalhoub M
    Clin Appl Thromb Hemost; 2020; 26():1076029620931194. PubMed ID: 32559127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
    Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
    Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin.
    Aleidan FAS; Aljarba GA; Aldakhil AA; Allehyani BI; Yahia MA; Alghtani NE; Badri M; Alaklabi AA; Alsuhaibani A; Crowther MA
    Int J Hematol; 2020 Jul; 112(1):1-7. PubMed ID: 32266670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical Procedure.
    Pannucci CJ; Fleming KI; Holoyda K; Moulton L; Prazak AM; Varghese TK
    Ann Thorac Surg; 2018 Aug; 106(2):404-411. PubMed ID: 29626461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin for venous thromboembolism prophylaxis in general Intensive Care Unit patients: an anti-factor Xa level-based approach.
    Zohar N; Ellis MH; Dichtwald S; Meyer A; Zohar E; Ifrach N
    Minerva Anestesiol; 2023 May; 89(5):425-433. PubMed ID: 36326777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is monitoring of anti-factor Xa levels required for low molecular weight heparin prophylaxis of venous thromboembolism in critically ill patients?].
    Ding M; Ning Y; Song L; Li P; Xie F; Li S; Wang C
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2024 May; 36(5):461-464. PubMed ID: 38845490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adequacy of Fixed-Dose Heparin Infusions for Venous Thromboembolism Prevention after Microsurgical Procedures.
    Bertolaccini CM; Prazak AMB; Agarwal J; Goodwin IA; Rockwell WB; Pannucci CJ
    J Reconstr Microsurg; 2018 Nov; 34(9):729-734. PubMed ID: 29788512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis.
    Wu T; Xia X; Chen W; Fu J; Zhang J
    J Clin Pharm Ther; 2020 Aug; 45(4):602-608. PubMed ID: 32449992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Anti-Factor Xa Level Predicts 90-Day Symptomatic Venous Thromboembolism in Surgical Patients Receiving Enoxaparin Prophylaxis: A Pooled Analysis of Eight Clinical Trials.
    Pannucci CJ; Fleming KI; Varghese TK; Stringham J; Huang LC; Pickron TB; Prazak AM; Bertolaccini C; Momeni A
    Ann Surg; 2022 Dec; 276(6):e682-e690. PubMed ID: 33086312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review.
    Ribic C; Lim W; Cook D; Crowther M
    J Crit Care; 2009 Jun; 24(2):197-205. PubMed ID: 19327323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are We Missing Treatment Standards for Thromboprophylaxis of the Obese and Super-Obese Patient Population? A Prospective Systematic Cohort Study.
    Stier C; Koschker AC; Stier R; Sosnierz A; Chiappetta S
    Obes Surg; 2020 May; 30(5):1704-1711. PubMed ID: 31974866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Underdosing of Prophylactic Enoxaparin Is Common in Orthopaedic Trauma and Predicts 90-Day Venous Thromboembolism.
    Jones DL; Jones WA; Fleming KI; Higgins TF; Rothberg DL; Zhang Y; Pannucci CJ
    J Orthop Trauma; 2019 Nov; 33(11):570-576. PubMed ID: 31634287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.